Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Net Cash Flow (2023 - 2025)

Bioharvest Sciences has reported Net Cash Flow over the past 3 years, most recently at $12.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 3688.96% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $20.6 million, up 802.7%, while the annual FY2025 figure was $20.6 million, 802.7% up from the prior year.
  • Net Cash Flow was $12.0 million for Q4 2025 at Bioharvest Sciences, up from $7.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $12.0 million in Q4 2025 and bottomed at -$2.4 million in Q3 2024.
  • The 3-year median for Net Cash Flow is $676500.0 (2025), against an average of $2.1 million.
  • Year-over-year, Net Cash Flow crashed 850.4% in 2024 and then skyrocketed 3688.96% in 2025.
  • Over 3 years, Net Cash Flow stood at $3.7 million in 2023, then plummeted by 109.0% to -$335000.0 in 2024, then skyrocketed by 3688.96% to $12.0 million in 2025.
  • The last three reported values for Net Cash Flow were $12.0 million (Q4 2025), $7.2 million (Q3 2025), and $338000.0 (Q2 2025) per Business Quant data.